Gilead Sciences, Inc.

Gilead Science is a biopharmaceutical research based company, which discovers, develops and commercializes innovative medicines for the unmet needs in the different areas in this field. The company is trying to improve in the area of medicine by providing people who are suffering from various diseases, which are fatal by discovering and experimenting new medicines.

The main focus of the company is on discovering antiviral medicines for diseases such as HIV/AIDS and chronic hepatitis, cardio vascular conditions such as pulmonary arterial hypertension and resistant hypertension and respiratory diseases like influenza and cystic fibrosis.

The company’s markets products like Atripla®, which is the first single tablet regimen for HIV infection. The scientists of this company also invented anti-influenza drug Tamiflu®, which is globally marketed by Hoffmann-La Roche. The latest therapy of the company, which was approved in June 2007 is Letairis® and there is also a once-daily oral treatment for pulmonary arterial hypertension.

The company was founded in 1987 in Foster City, California and in just 20 years it became one of the largest biopharmaceutical companies in the world. The company has an expanding product portfolio, growing pipeline of investigational drugs, with more than 3,200 employees. The company operates in three continents. The company was ranked third by the “Business Week” magazine in it’s 2007 list of the top best performing 50 companies.

The research and development program of Gilead’s identifies and evaluates compounds that show potential to improve the treatment of life threatening diseases. At present they are developing several drugs in its focused therapeutic areas too.